High levels of chromosomal instability facilitate the tumor growth and sphere formation.


Journal

Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776

Informations de publication

Date de publication:
Aug 2022
Historique:
revised: 19 05 2022
received: 09 02 2022
accepted: 02 06 2022
pubmed: 7 6 2022
medline: 10 8 2022
entrez: 6 6 2022
Statut: ppublish

Résumé

Most cancer cells show chromosomal instability (CIN), a condition in which chromosome missegregation occurs at high rates. Growing evidence suggests that CIN is not just a consequence of, but a driving force for, oncogenic transformation, although the relationship between CIN and tumorigenesis has not been fully elucidated. Here we found that conventional two-dimensional (2D) culture of HeLa cells, a cervical cancer-derived cell line, was a heterogenous population containing cells with different CIN levels. Although cells with high-CIN levels (high-CIN cells) grew more slowly compared with cells with low-CIN levels (low-CIN cells) in 2D monolayer culture, they formed tumors in nude mice and larger spheres in three-dimensional (3D) culture, which was more representative of the in vivo environment. The duration of mitosis was longer in high-CIN cells, reflecting their higher mitotic defects. Single-cell genome sequencing revealed that high-CIN cells exhibited a higher karyotype heterogeneity compared with low-CIN cells. Intriguingly, the karyotype heterogeneity was reduced in the spheres formed by high-CIN cells, suggesting that cells with growth advantages were selected, although genomic copy number changes specific for spheres were not identified. When we examined gene expression profiles, genes related to the K-ras signaling were upregulated, while those related to the unfolded protein response were downregulated in high-CIN cells in 3D culture compared with 2D culture, suggesting the relevance of these genes for their survival. Our data suggested that, although CIN is disadvantageous in monolayer culture, it promotes the selection of cells with growth advantages under in vivo environments, which may lead to tumorigenesis.

Identifiants

pubmed: 35662350
doi: 10.1111/cas.15457
pmc: PMC9357619
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2727-2737

Subventions

Organisme : Canon Medical Systems Corporation
Organisme : Gonryo Medical Foundation
Organisme : Japan Science and Technology Agency
ID : JPMJAX2112
Organisme : Japan Society for the Promotion of Science
ID : 16H06279
Organisme : Japan Society for the Promotion of Science
ID : 16H06635
Organisme : Japan Society for the Promotion of Science
ID : 18H02434
Organisme : Japan Society for the Promotion of Science
ID : 18K15234
Organisme : Japan Society for the Promotion of Science
ID : 20K16295
Organisme : Japan Society for the Promotion of Science
ID : 22H02614
Organisme : Kanae Foundation for the Promotion of Medical Science
Organisme : Ministry of Education, Culture, Sports, Science and Technology
ID : 18H04896
Organisme : Ministry of Education, Culture, Sports, Science and Technology
ID : 21H05738
Organisme : Takeda Science Foundation
Organisme : Uehara Memorial Foundation
Organisme : Yamaguchi Ikuei Foundation

Informations de copyright

© 2022 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

Références

Methods. 2017 Feb 15;115:80-90
pubmed: 27713081
Nat Rev Mol Cell Biol. 2015 Aug;16(8):473-85
pubmed: 26204159
Sci Rep. 2017 Aug 18;7(1):8794
pubmed: 28821799
Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14188-93
pubmed: 20663956
J Clin Invest. 2012 Apr;122(4):1138-43
pubmed: 22466654
Nature. 2010 Apr 1;464(7289):721-7
pubmed: 20360735
BMC Bioinformatics. 2019 Jun 17;20(1):336
pubmed: 31208319
Cancer Sci. 2013 Jul;104(7):871-9
pubmed: 23551833
Trends Genet. 2011 Nov;27(11):446-53
pubmed: 21872963
Cell Rep. 2015 Aug 4;12(5):809-20
pubmed: 26212324
Nature. 2010 Feb 18;463(7283):899-905
pubmed: 20164920
Genes Dev. 2021 Aug 1;35(15-16):1079-1092
pubmed: 34266888
Dev Cell. 2018 Feb 26;44(4):420-431
pubmed: 29486194
J Cell Biol. 2021 Jul 5;220(7):
pubmed: 33988677
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Nat Rev Cancer. 2014 May;14(5):359-70
pubmed: 24739573
Genes Dev. 2021 Aug 1;35(15-16):1093-1108
pubmed: 34266887
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
Genome Biol. 2016 May 31;17(1):115
pubmed: 27246460
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Cell. 2017 Feb 9;168(4):613-628
pubmed: 28187284
Cold Spring Harb Perspect Med. 2017 Jun 1;7(6):
pubmed: 28213433
Cell Cycle. 2019 Aug;18(15):1702-1713
pubmed: 31179849
Cancer Cell. 2018 Apr 9;33(4):676-689.e3
pubmed: 29622463
Nat Rev Mol Cell Biol. 2012 Jan 18;13(2):89-102
pubmed: 22251901
Front Oncol. 2013 Jun 27;3:164
pubmed: 23825799
Nature. 2013 Aug 8;500(7461):207-11
pubmed: 23925245
Trends Biotechnol. 2013 Feb;31(2):108-15
pubmed: 23336996
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
EMBO Rep. 2012 Jun 01;13(6):528-38
pubmed: 22595889
Dev Cell. 2021 Sep 13;56(17):2427-2439.e4
pubmed: 34352222
Sci Transl Med. 2015 Apr 15;7(283):283ps9
pubmed: 25877888
Bioinformatics. 2019 Nov 15;:
pubmed: 31730197
Biochim Biophys Acta. 2016 Aug;1866(1):64-75
pubmed: 27345585
EMBO J. 2011 Jan 5;30(1):130-44
pubmed: 21063390
Dev Cell. 2021 Sep 13;56(17):2440-2454.e6
pubmed: 34352223
BMC Bioinformatics. 2018 Dec 19;19(1):534
pubmed: 30567491
Biochem J. 2000 Oct 15;351 Pt 2:289-305
pubmed: 11023813
Sci Rep. 2018 Mar 1;8(1):3888
pubmed: 29497093
Cancers (Basel). 2021 Nov 09;13(22):
pubmed: 34830757
BMC Bioinformatics. 2014;15 Suppl 2:S2
pubmed: 24564555
Front Oncol. 2013 Jun 07;3:148
pubmed: 23760367
Front Physiol. 2017 Aug 22;8:605
pubmed: 28878686
J Cell Biol. 2010 Feb 8;188(3):369-81
pubmed: 20123995
Proc Natl Acad Sci U S A. 2020 Aug 18;117(33):20004-20014
pubmed: 32747568
Genetics. 2008 Jun;179(2):737-46
pubmed: 18558649
Genome Res. 2012 Oct;22(10):1995-2007
pubmed: 22637570
J Biotechnol. 2010 Jul 1;148(1):3-15
pubmed: 20097238
Nature. 2015 Jun 11;522(7555):179-84
pubmed: 26017310
PLoS One. 2012;7(11):e49752
pubmed: 23152931
Cancer Sci. 2022 Aug;113(8):2727-2737
pubmed: 35662350
Nat Rev Cancer. 2021 Feb;21(2):89-103
pubmed: 33432169
J Cell Sci. 2014 Jul 1;127(Pt 13):2818-24
pubmed: 24777477
Nat Commun. 2020 Mar 20;11(1):1501
pubmed: 32198375
Exp Biol Med (Maywood). 2014 Sep;239(9):1240-54
pubmed: 24740872

Auteurs

Kenji Iemura (K)

Department of Molecular Oncology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan.

Hayato Anzawa (H)

Department of Applied Information Sciences, Graduate School of Information Sciences, Tohoku University, Sendai, Japan.

Ryo Funayama (R)

Department of Cell Proliferation, ART, Graduate School of Medicine, Tohoku University, Sendai, Japan.

Runa Iwakami (R)

Department of Molecular Oncology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan.

Keiko Nakayama (K)

Department of Cell Proliferation, ART, Graduate School of Medicine, Tohoku University, Sendai, Japan.

Kengo Kinoshita (K)

Department of Applied Information Sciences, Graduate School of Information Sciences, Tohoku University, Sendai, Japan.
Tohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Advanced Research Center for Innovations in Next-Generation Medicine, Tohoku University, Sendai, Japan.

Kozo Tanaka (K)

Department of Molecular Oncology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH